Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

860624P

Avanti

C18:1 Dihydroceramide (d18:0/18:1(9Z))

Avanti Research™ - A Croda Brand 860624P, powder

Synonyme(s) :

N-oleoyl-D-erythro-sphinganine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Sélectionner une taille de conditionnement

5 MG
116,00 €

116,00 €

Check Cart for Availability
Devis pour commande en gros
Toutes les photos(1)

Sélectionner une taille de conditionnement

Changer de vue
5 MG
116,00 €

About This Item

Formule empirique (notation de Hill) :
C36H71NO3
Numéro CAS:
34227-83-3
Poids moléculaire :
565.95
Numéro MDL:
MFCD22495332
Code UNSPSC :
12352211
Nomenclature NACRES :
NA.25

116,00 €

Check Cart for Availability
Devis pour commande en gros

Forme

powder

Conditionnement

pkg of 1 × 5 mg (860624P-5mg)

Fabricant/nom de marque

Avanti Research™ - A Croda Brand 860624P

Type de lipide

sphingolipids

Conditions d'expédition

dry ice

Température de stockage

−20°C

Chaîne SMILES 

OC[C@]([H])(NC(CCCCCCC/C=C\CCCCCCCC)=O)[C@]([H])(O)CCCCCCCCCCCCCCC

InChI

1S/C36H71NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,34-35,38-39H,3-16,19-33H2,1-2H3,(H,37,40)/b18-17-/t34-,35+/m0/s1

Clé InChI

MJQIARGPQMNBGT-WWUCIAQXSA-N

Description générale

C18:1 Dihydroceramide (d18:0/18:1(9Z)) is a synthetic lipid. Dihydroceramide belongs to the ceramide family. It contains sphinganine, which is devoid of the 4,5-trans-double bond in the sphingoid base backbone.[1]

Application

C18:1 Dihydroceramide (d18:0/18:1(9Z)) has been used as an internal standard to quantify the levels of serum and skeletal muscle lipids extracted from muscle tissue by liquid chromatography-mass spectrometry (MS) analysis.[2] It has also been used as an standard to study its structural characterization by positive-ionization mode 193 nm ultraviolet photodissociation (UVPD)-mass spectrometry/MS.[3]

Actions biochimiques/physiologiques

Dihydroceramide is synthesized by the N-acylation of dihydrosphingosine.[4] It functions as an inactive precursor[5] for ceramide in de-novo sphingolipid synthesis.[4] (Dihydro)-ceramide desaturase catalyzes the conversion of dihydroceramide to ceramide by the addition of C4–5 trans-double bond in the sphingoid backbone.[1] Dihydroceramide has an ability to induce autophagy.[5]

Conditionnement

5 mL Amber Glass Screw Cap Vial (860624P-5mg)

Informations légales

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Souvent commandé avec ce produit

Réf. du produit
Description
Tarif

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Skeletal muscle ceramides and relationship with insulin sensitivity after 2 weeks of simulated sedentary behaviour and recovery in healthy older adults
Reidy PT, et al.
The Journal of Physiology, 596(21), 5217-5236 (2018)
B K Gillard et al.
Glycobiology, 8(9), 885-890 (1998-07-24)
There are several pathways for the incorporation of sugars into glycosphingolipids (GSL). Sugars can be added to ceramide that contains sphinganine (dihydrosphingosine) synthesized de novo (pathway 1), to ceramide synthesized from sphingoid bases produced by hydrolysis of sphingolipids (pathway 2)
Detailed structural characterization of sphingolipids via 193 nm ultraviolet photodissociation and ultrahigh resolution tandem mass spectrometry
Ryan E, et al.
Journal of the American Society For Mass Spectrometry, 28(7), 1406-1419 (2017)
Sexual dimorphism in activation of placental autophagy in obese women with evidence for fetal programming from a placenta-specific mouse model
Muralimanoharan S, et al.
Autophagy, 12(5), 752-769 (2016)
Sribalasubashini Muralimanoharan et al.
Autophagy, 12(5), 752-769 (2016-03-18)
The incidence of maternal obesity and its co-morbidities (diabetes, cardiovascular disease) continues to increase at an alarming rate, with major public health implications. In utero exposure to maternal obesity has been associated with development of cardiovascular and metabolic diseases in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique